Health‐related quality of life in patients with relapsed/refractory multiple myeloma treated with pomalidomide and dexamethasone ± subcutaneous daratumumab: Patient‐reported outcomes from the APOLLO trial
Sign Up to like & getrecommendations! Published in 2022 at "American Journal of Hematology"
DOI: 10.1002/ajh.26480
Abstract: In the phase 3 APOLLO trial, daratumumab in combination with pomalidomide and dexamethasone (D‐Pd) significantly reduced the rate of disease progression or death by 37% relative to Pd alone in patients with relapsed/refractory multiple myeloma… read more here.
Keywords: pomalidomide dexamethasone; daratumumab; health; relapsed refractory ... See more keywords
Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma
Sign Up to like & getrecommendations! Published in 2018 at "Cancer"
DOI: 10.1002/cncr.31706
Abstract: Daratumumab is a human CD38‐directed monoclonal antibody indicated for the treatment of relapsed and refractory multiple myeloma (MM). read more here.
Keywords: relapsed refractory; refractory multiple; treatment; multiple myeloma ... See more keywords
Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re‐treatment with daratumumab among refractory patients
Sign Up to like & getrecommendations! Published in 2019 at "Cancer"
DOI: 10.1002/cncr.32178
Abstract: The efficacy of daratumumab (DARA) both as a monotherapy and in combination with standard‐of‐care regimens in multiple myeloma (MM) has been established in clinical trials. This article presents a retrospective analysis of the safety and… read more here.
Keywords: daratumumab pomalidomide; efficacy; pomalidomide dexamethasone; efficacy daratumumab ... See more keywords
Response to “The Role of FcRn in the Pharmacokinetics of Biologics in Patients with Multiple Myeloma”
Sign Up to like & getrecommendations! Published in 2017 at "Clinical Pharmacology and Therapeutics"
DOI: 10.1002/cpt.779
Abstract: To the Editor: Daratumumab, a therapeutic immunoglobulin G (IgG) 1j monoclonal antibody, targets CD38 for the treatment of multiple myeloma. In our article, we reported that daratumumab exhibited time-dependent and concentration-dependent pharmacokinetics (PK) consistent with… read more here.
Keywords: igg; response; multiple myeloma; igg patients ... See more keywords
Exposure‐Response and Population Pharmacokinetic Analyses of a Novel Subcutaneous Formulation of Daratumumab Administered to Multiple Myeloma Patients
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Pharmacology"
DOI: 10.1002/jcph.1771
Abstract: We report the population pharmacokinetic (PK) and exposure‐response analyses of a novel subcutaneous formulation of daratumumab (DARA) using data from 3 DARA subcutaneous monotherapy studies (PAVO Part 2, MMY1008, COLUMBA) and 1 combination therapy study… read more here.
Keywords: exposure response; intravenous dara; dara; monotherapy ... See more keywords
Long-term response to daratumumab in a patient with advanced immunoglobulin light-chain (AL) amyloidosis with organ damage
Sign Up to like & getrecommendations! Published in 2018 at "Annals of Hematology"
DOI: 10.1007/s00277-018-3566-4
Abstract: Dear Editor, Light-chain (AL) amyloidosis with organ damage remains an unmet medical need with significant associated morbidity and mortality, especially for those patients with relapsed or refractory (R/R) disease with cardiac involvement [1, 2]. Daratumumab,… read more here.
Keywords: light chain; response; damage; daratumumab ... See more keywords
Prolonged severe neutropenia after the first daratumumab administration for multiple myeloma with baseline neutropenia
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Hematology"
DOI: 10.1007/s00277-019-03711-0
Abstract: Dear Editor, Daratumumab, an anti-CD38 monoclonal antibody, shows substantial efficacy for relapsed and refractory multiple myeloma (MM). Daratumumab also has a clinically manageable and acceptable safety profile. Grade 3–4 neutropenia was recorded in 5–12% of… read more here.
Keywords: treatment; severe neutropenia; therapy; neutropenia ... See more keywords
Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses
Sign Up to like & getrecommendations! Published in 2020 at "Advances in Therapy"
DOI: 10.1007/s12325-020-01247-8
Abstract: Introduction Daratumumab, a human immunoglobulin Gκ monoclonal antibody targeting CD38, is approved as monotherapy and in combination with standard-of-care regimens for multiple myeloma. In clinical studies, the median durations of the first, second, and subsequent… read more here.
Keywords: first dose; treatment; multiple myeloma; daratumumab ... See more keywords
Assessment of Healthcare Professionals’ Knowledge and Understanding of the Risk of Blood Typing Interference with Daratumumab: A Survey of 12 European Countries
Sign Up to like & getrecommendations! Published in 2021 at "Advances in Therapy"
DOI: 10.1007/s12325-021-01685-y
Abstract: Daratumumab, a monoclonal antibody targeting CD38, is approved to treat multiple myeloma. Red blood cells express low levels of CD38, which can result in a false-positive antibody screen in daratumumab-treated patients. Educational materials were developed… read more here.
Keywords: european countries; risk; survey; blood ... See more keywords
Outcomes of anti-CD38 isatuximab plus pomalidomide and dexamethasone in five relapsed myeloma patients with prior exposure to anti-C38 daratumumab: case series.
Sign Up to like & getrecommendations! Published in 2022 at "Hematology"
DOI: 10.1080/16078454.2022.2028978
Abstract: Objectives: Daratumumab is the first anti-CD38 monoclonal antibody (Mab) used to treat myeloma in the newly diagnosed setting and in the relapsed setting. Isatuximab, another Mab targeting a specific epitope on the CD38 receptor, was… read more here.
Keywords: myeloma patients; two patients; daratumumab; case series ... See more keywords
False positive results: a challenge for laboratory physicians and hematologists in treating multiple myeloma with daratumumab
Sign Up to like & getrecommendations! Published in 2022 at "Hematology"
DOI: 10.1080/16078454.2022.2045723
Abstract: ABSTRACT Daratumumab injection was approved by China in 2019 for the treatment of recurrent or refractory multiple myeloma. However, the molecular weight of daratumumab, an immunoglobin G1 kappa human monoclonal antibody, was similar to that… read more here.
Keywords: daratumumab; positive results; results challenge; false positive ... See more keywords